Prognostic stratification in venetoclax-based acute myeloid leukemia treatments: the molecular prognostic risk signature tested in a real-world setting

Haematologica. 2025 Jan 1;110(1):239-243. doi: 10.3324/haematol.2024.285934.
No abstract available

Grants and funding

Funding: This work received financial support from Associazione Italiana per la Ricerca sul Cancro (AIRC) 5×1000 called “Metastatic disease: the key unmet need in oncology” to MYNERVA (MYeloid NEoplasms Research Venture AIRC), project #21267. It was also supported by a legacy from the Zottola family to UNIFI.